Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867251 · ClinicalTrials.gov registry record · Phase 1
Study of AVZO-021 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, sponsored by Avenzo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 430
- Enrollment target
- 13
- Study locations
NCT05867251 is a Phase 1 study of Advanced Solid Tumor and Endometrial Cancer that is actively recruiting participants, run by Avenzo Therapeutics. The registered enrollment target is 430 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (125% higher). The trial reports 13 study locations across 10 states.
The verdict
NCT05867251, a Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, is actively recruiting participants, sponsored by Avenzo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 430 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Fulvestrant
- DRUG Palbociclib
- DRUG AVZO-021
- DRUG Ribociclib
Study Locations (13)
Florida
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center - Tampa
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
- NYU Langone Medical Center (Tisch Hospital) - New York
New South Wales
- Macquarie University Hospital - Macquarie University
- Cancer Care Wollongong - Wollongong
Connecticut
- Yale Cancer Center - New Haven
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Oklahoma
- Oklahoma University - Oklahoma City
Oregon
- Providence Cancer Institute - Portland
Pennsylvania
- Sidney Kimmel Cancer Center (SKCC) at Jefferson Health - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05867251
The ClinicalTrials.gov registry entry for NCT05867251 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (125% higher). The listed sponsor is Avenzo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Letrozole is the first listed.
NCT05867251 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Florida, New York, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05867251 about?
NCT05867251 is a clinical study titled "Study of AVZO-021 in Patients With Advanced Solid Tumors". This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 ...
What is the current status of trial NCT05867251?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 430 participants. The study started on 2023-08-30. Estimated completion is 2030-01-31.
What conditions does trial NCT05867251 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Endometrial Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT05867251?
The interventions under investigation include: Letrozole (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG), AVZO-021 (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT05867251?
This trial is sponsored by Avenzo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05867251 being conducted?
This trial has 13 study locations across Connecticut, Florida, New York, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.